Justin Annes, MD, PhD Stanford University
- Status: Completed
- Year(s): 2018
- Grant Type: Pilot
- Research Type: Translational
- Primary Tumor Site: Pancreas
- Area of Inquiry: Signaling/drug targets
By taking advantage of unique properties of NETs that are not found in healthy cells, researchers will try to target chemotherapy to attack only cancer cells, instead of all cells. Creating novel chemotherapeutic agents that will attack and kill only NET cells, will help reduce the side effects of currently used systemic chemotherapy.
Horton TM, Sundaram V, Hye-Jin Lee C, et al. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Scientific Reports. 2020; (10):10943.
We have continued to advance our effort to develop NET-targeted therapeutics. At this point we have robust biochemical and cellular data which have moved our platform technology from theoretically possible to demonstrable achievable.
- City: Stanford
- State: California
- Grant Duration: 1 year
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.